<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font3" size="7" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font4" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font5" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font6" size="8" family="AkzidenzGroteskBE" color="#ffffff"/>
<text top="42" left="315" width="241" height="7" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="text">Available online http://breast-cancer-research.com/content/8/6/R66<b>Available online</b></text>
<text top="758" left="511" width="45" height="7" font="font2" id="p1_t2" reading_order_no="45" segment_no="10" tag_type="text">Page 9 of 12</text>
<text top="769" left="436" width="120" height="6" font="font3" id="p1_t3" reading_order_no="46" segment_no="11" tag_type="text">(page number not for citation purposes)</text>
<text top="203" left="57" width="240" height="9" font="font4" id="p1_t4" reading_order_no="20" segment_no="5" tag_type="text">small, although the identical response rates in women with<i>(page number not for citation purposes)</i></text>
<text top="214" left="57" width="240" height="9" font="font4" id="p1_t5" reading_order_no="21" segment_no="5" tag_type="text">HER2-positive tumors and those with HER2-negative tumors</text>
<text top="226" left="57" width="240" height="9" font="font4" id="p1_t6" reading_order_no="22" segment_no="5" tag_type="text">suggests that a substantial difference in response rates would</text>
<text top="238" left="57" width="115" height="9" font="font4" id="p1_t7" reading_order_no="23" segment_no="5" tag_type="text">be unlikely in a larger sample.</text>
<text top="261" left="57" width="240" height="9" font="font4" id="p1_t8" reading_order_no="24" segment_no="7" tag_type="text">Our data showed that hormone receptor status is important as</text>
<text top="273" left="57" width="240" height="9" font="font4" id="p1_t9" reading_order_no="25" segment_no="7" tag_type="text">a prognostic factor in this study but was not predictive of</text>
<text top="285" left="57" width="240" height="9" font="font4" id="p1_t10" reading_order_no="26" segment_no="7" tag_type="text">clinical response or TTF after paclitaxel therapy. Conflicting</text>
<text top="297" left="57" width="240" height="9" font="font4" id="p1_t11" reading_order_no="27" segment_no="7" tag_type="text">data have been reported regarding the role of ER in predicting</text>
<text top="308" left="57" width="240" height="9" font="font4" id="p1_t12" reading_order_no="28" segment_no="7" tag_type="text">benefit from taxane therapy. In CALGB 9344, a subgroup</text>
<text top="203" left="315" width="241" height="9" font="font4" id="p1_t13" reading_order_no="29" segment_no="6" tag_type="text">analysis demonstrated that the addition of paclitaxel in the</text>
<text top="214" left="315" width="240" height="9" font="font4" id="p1_t14" reading_order_no="30" segment_no="6" tag_type="text">adjuvant setting was more beneficial in women with ER/PR-</text>
<text top="226" left="315" width="240" height="9" font="font4" id="p1_t15" reading_order_no="31" segment_no="6" tag_type="text">negative tumors than in those with ER/PR-positive tumors [1].</text>
<text top="238" left="315" width="240" height="9" font="font4" id="p1_t16" reading_order_no="32" segment_no="6" tag_type="text">This observation is supported by a combined analysis con-<a href="">[1].</a></text>
<text top="250" left="315" width="240" height="9" font="font4" id="p1_t17" reading_order_no="33" segment_no="6" tag_type="text">ducted by Henderson and coworkers [41], which demon-</text>
<text top="261" left="315" width="241" height="9" font="font4" id="p1_t18" reading_order_no="34" segment_no="6" tag_type="text">strated a strong relationship between ER/PR negativity and a<a href="">rkers [41], w</a>hich demon-</text>
<text top="273" left="315" width="240" height="9" font="font4" id="p1_t19" reading_order_no="35" segment_no="6" tag_type="text">benefit from chemotherapy. However, the results of the</text>
<text top="285" left="315" width="240" height="9" font="font4" id="p1_t20" reading_order_no="36" segment_no="6" tag_type="text">NSABP B-28 trial [2] and the Breast Cancer International</text>
<text top="297" left="315" width="240" height="9" font="font4" id="p1_t21" reading_order_no="37" segment_no="6" tag_type="text">Research Group (BCIRG) 001 trial [42] do not support this<a href="">ABP B-28 trial [2</a>] and the Breast Cancer International</text>
<text top="308" left="315" width="240" height="9" font="font4" id="p1_t22" reading_order_no="38" segment_no="6" tag_type="text">finding. Our study suggests that differences in survival as a<a href="">l [42] do not support this</a></text>
<text top="85" left="57" width="28" height="7" font="font0" id="p1_t23" reading_order_no="1" segment_no="1" tag_type="title">Table 6</text>
<text top="104" left="57" width="154" height="7" font="font0" id="p1_t24" reading_order_no="2" segment_no="2" tag_type="text">HER2 status and median overall survival<b>Table 6</b></text>
<text top="123" left="61" width="103" height="7" font="font2" id="p1_t25" reading_order_no="3" segment_no="3" tag_type="table">Method for ascertaining HER2<b>HER2 status and median overall survival</b></text>
<text top="123" left="186" width="49" height="7" font="font2" id="p1_t26" reading_order_no="4" segment_no="3" tag_type="table">HER2 positive</text>
<text top="123" left="310" width="51" height="7" font="font2" id="p1_t27" reading_order_no="5" segment_no="3" tag_type="table">HER2 negative</text>
<text top="123" left="435" width="56" height="7" font="font2" id="p1_t28" reading_order_no="6" segment_no="3" tag_type="table">Log-rank P value</text>
<text top="139" left="61" width="21" height="7" font="font2" id="p1_t29" reading_order_no="7" segment_no="3" tag_type="table">CB11</text>
<text top="139" left="186" width="43" height="7" font="font2" id="p1_t30" reading_order_no="8" segment_no="3" tag_type="table">11.3 months<i>P </i></text>
<text top="139" left="310" width="43" height="7" font="font2" id="p1_t31" reading_order_no="9" segment_no="3" tag_type="table">13.1 months</text>
<text top="139" left="435" width="16" height="7" font="font2" id="p1_t32" reading_order_no="10" segment_no="3" tag_type="table">0.14</text>
<text top="154" left="61" width="17" height="7" font="font2" id="p1_t33" reading_order_no="11" segment_no="3" tag_type="table">FISH</text>
<text top="154" left="186" width="43" height="7" font="font2" id="p1_t34" reading_order_no="12" segment_no="3" tag_type="table">10.9 months</text>
<text top="154" left="310" width="43" height="7" font="font2" id="p1_t35" reading_order_no="13" segment_no="3" tag_type="table">13.1 months</text>
<text top="154" left="435" width="16" height="7" font="font2" id="p1_t36" reading_order_no="14" segment_no="3" tag_type="table">0.26</text>
<text top="170" left="61" width="99" height="7" font="font2" id="p1_t37" reading_order_no="15" segment_no="3" tag_type="table">HercepTest: 2–3 versus 0–1</text>
<text top="170" left="186" width="43" height="7" font="font2" id="p1_t38" reading_order_no="16" segment_no="3" tag_type="table">11.5 months</text>
<text top="170" left="310" width="43" height="7" font="font2" id="p1_t39" reading_order_no="17" segment_no="3" tag_type="table">13.2 months</text>
<text top="170" left="435" width="16" height="7" font="font2" id="p1_t40" reading_order_no="18" segment_no="3" tag_type="table">0.84</text>
<text top="186" left="61" width="134" height="7" font="font2" id="p1_t41" reading_order_no="19" segment_no="4" tag_type="text">FISH, fluorescence in situ hybridization.</text>
<text top="332" left="57" width="31" height="7" font="font0" id="p1_t42" reading_order_no="39" segment_no="8" tag_type="title">Figure 2</text>
<text top="690" left="57" width="272" height="7" font="font6" id="p1_t43" reading_order_no="40" segment_no="9" tag_type="text">Time to treatment failure and overall survival for triple-negative subgroup, by race</text>
<text top="690" left="57" width="499" height="7" font="font2" id="p1_t44" reading_order_no="41" segment_no="9" tag_type="text">Time to treatment failure and overall survival for triple-negative subgroup, by race. Time to treatment failure: (a) not triple negative and (b) triple neg-</text>
<text top="699" left="57" width="494" height="7" font="font2" id="p1_t45" reading_order_no="42" segment_no="9" tag_type="text">ative. Overall survival: (c) not triple negative and (d) triple negative. Patients were classified by race (African-American [dashed line] or Caucasian<i>in situ </i></text>
<text top="709" left="57" width="495" height="7" font="font2" id="p1_t46" reading_order_no="43" segment_no="9" tag_type="text">[solid line]) and divided into subsets based on triple-negative status. Exploratory analysis to investigate the interaction of triple negative status and</text>
<text top="718" left="57" width="17" height="7" font="font2" id="p1_t47" reading_order_no="44" segment_no="9" tag_type="text">race.<b>Figure 2</b></text>
</page>
</pdf2xml>
